LONDON— A change of therapy from chlorambucil to bendamustine was being recommended at the European Haematology Association annual meeting (June 8-12, 2011) for patients with chronic lymphocytic leuke
Wolfgang Knauf
LONDON— A change of therapy from chlorambucil to bendamustine was being recommended at the European Haematology Association annual meeting (June 8-12, 2011) for patients with chronic lymphocytic leukemia who are not fit enough to receive the gold-standard FCR chemo-immunotherapy. In a debate with Professor Peter Hillmen from Leeds University in England Wolfgang Knauf, Professor of Haematology from Frankfurt, Germany, opposed the motion that “chlorambucil is still the chemotherapy of choice” for this patient group.
More news from the EHA congress at http://www.ecancermedicalscience.com.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110614WoklfgangKnaufPODCASTLoRes.mp3]